Adding Ropeginterferon to Ruxolitinib for Myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests whether adding a type of interferon (ropeginterferon) to your current myelofibrosis treatment (ruxolitinib) is safe and tolerable. Myelofibrosis is a blood disorder where bone marrow becomes scarred; this combination might help control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis with specific genetic mutations (JAK2, CALR, or MPL)
- You have been on a stable dose of ruxolitinib for at least 6 weeks before joining the trial
- Your spleen is enlarged (larger than 450ml) confirmed by imaging
- Your blood tests show adequate kidney, liver, and blood cell function
- You are at least 18 years old and able to give informed consent
- If you can become pregnant, you must use reliable contraception and cannot be pregnant at the start
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests whether adding TL-895 to ruxolitinib can improve outcomes in adults with myelofibrosis. It focuses on people who are not getting enough benefit from ruxolitinib or who need treatment as part of the study.
This Phase 2 trial tests whether elritercept, given alone or together with ruxolitinib, can improve symptoms and disease control in adults with myelofibrosis. It may help people who have anemia and either cannot tolerate, can’t get enough benefit from, or are already using ruxolitinib.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
This trial tests a new drug called Navtemadlin when added to the standard treatment ruxolitinib for people with myelofibrosis who are not getting the best results from ruxolitinib alone. It may help improve response and control the disease.
This study tests whether a new drug called elritercept can help reduce the need for blood transfusions in adults with myelofibrosis (a bone marrow cancer) who are already taking ruxolitinib. The goal is to see if elritercept helps your body make more red blood cells naturally.
Hear when a new Myelofibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.